ImaginAb lands $13M in growth funding

By staff writers

June 3, 2021 -- Radiopharmaceutical developer ImaginAb has raised almost $13 million in funding to support the company's growth and further development of its CD8 Immuno-PET agent.

Immuno-PET is an antibody fragment (minibody) labeled with zirconium-89 that binds to the CD8 receptor on human T cells and is being developed for quantitative, noninvasive PET imaging of CD8 T cells in patients.

The company said the funding will be used to continue and expand clinical trials of CD8 Immuno-PET that are underway in over 20 hospitals in North America, Europe, and Australia.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking